Ferroportin in the progression and prognosis of hepatocellular carcinoma

European Journal of Medical Research

Volumn 18, Issue 1, 2013, Pages

  Wang, Qin ^a   Zhou, Jun ^a   Zhong, Dewu ^a   Wang, Qunwei ^a   Huang, Jiangsheng ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Ferroportin; Hepatocellular carcinoma; Prognosis

Indexed keywords

FERROPORTIN; CATION TRANSPORT PROTEIN; METAL TRANSPORTING PROTEIN 1;

ADULT; ARTICLE; CANCER GRADING; CANCER GROWTH; CANCER PROGNOSIS; CANCER STAGING; CELL DIFFERENTIATION; CELL STRAIN HEPG2; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER CELL; LIVER CELL CARCINOMA; LIVER METASTASIS; LIVER RESECTION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PORTAL VEIN; PROTEIN EXPRESSION; TUMOR INVASION; WESTERN BLOTTING; CLINICAL FEATURE; LIVER CANCER CELL LINE; SCORING SYSTEM; DISEASE COURSE; LIVER TUMOR; METABOLISM; PATHOLOGY; PROGNOSIS; TUMOR CELL LINE;

CARCINOMA, HEPATOCELLULAR; CATION TRANSPORT PROTEINS; CELL LINE, TUMOR; DISEASE PROGRESSION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS;

EID: 84890523743     PISSN: 09492321     EISSN: 2047783X     Source Type: Journal    
DOI: 10.1186/2047-783X-18-59     Document Type: Article

References (38)

1. Global cancer statistics. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D, CA Cancer J Clin 2011 61 69 90 10.3322/caac.20107 21296855
2. Estimating the world cancer burden: Globocan 2000. Parkin DM, Bray F, Ferlay J, Pisani P, Int J Cancer 2001 94 153 156 10.1002/ijc.1440 11668491 (Pubitemid 32911406)
3. Global cancer statistics, 2002. Parkin DM, Bray F, Ferlay J, Pisani P, CA Cancer J Clin 2005 55 74 108 10.3322/canjclin.55.2.74 15761078 (Pubitemid 40372904)
4. Hepatocellular carcinoma. Okuda K, J Hepatol 2000 32 225 237 10728807 (Pubitemid 30123637)
5. Abdominal obesity, weight gain during adulthood and risk of liver and biliary tract cancer in a European cohort. Schlesinger S, Aleksandrova K, Pischon T, Fedirko V, Jenab M, Trepo E, Boffetta P, Dahm CC, Overvad K, Tjonneland A, Halkjær J, Fagherazzi G, Boutron-Ruault MC, Carbonnel F, Kaaks R, Lukanova A, Boeing H, Trichopoulou A, Bamia C, Lagiou P, Palli D, Grioni S, Panico S, Tumino R, Vineis P, Bueno-de-Mesquita HB, van den Berg S, Peeters PH, Braaten T, Weiderpass E, et al. Int J Cancer 2013 132 645 657 10.1002/ijc.27645 22618881
6. Continual presence of oxygen and iron required for mammalian ribonucleotide reduction: possible regulation mechanism. Thelander L, Graslund A, Thelander M, Biochem Biophys Res Commun 1983 110 859 865 10.1016/0006- 291X(83)91040-9 6340669
7. Ironing out cancer. Torti SV, Torti FM, Cancer Res 2011 71 1511 1514 10.1158/0008-5472.CAN-10-3614 21363917
8. Dietary iron enhances the tumor rate in dimethylhydrazine-induced colon carcinogenesis in mice. Siegers CP, Bumann D, Baretton G, Younes M, Cancer Lett 1988 41 251 256 10.1016/0304-3835(88)90285-6 3409203
9. Iron as a synergist for hepatocellular carcinoma induced by polychlorinated biphenyls in Ah-responsive C57BL/10ScSn mice. Smith AG, Francis JE, Carthew P, Carcinogenesis 1990 11 437 444 10.1093/carcin/11.3.437 2155720 (Pubitemid 20079397)
10. Iron nutrition and tumor growth: decreased tumor growth in iron-deficient mice. Hann HW, Stahlhut MW, Blumberg BS, Cancer Res 1988 48 4168 4170 3390810
11. Iron enhances tumor growth. Observation on spontaneous mammary tumors in mice. Hann HW, Stahlhut MW, Menduke H, Cancer 1991 68 2407 2410 10.1002/1097-0142(19911201)68:11<2407::AID-CNCR2820681113>3.0.CO;2-N 1657354
12. Tumorigenic properties of iron regulatory protein 2 (IRP2) mediated by its specific 73-amino acids insert. Maffettone C, Chen G, Drozdov I, Ouzounis C, Pantopoulos K, PLoS One 2010 5 10163 10.1371/journal.pone.0010163 20405006
13. Overexpression of iron regulatory protein 1 suppresses growth of tumor xenografts. Chen G, Fillebeen C, Wang J, Pantopoulos K, Carcinogenesis 2007 28 785 791 17127713 (Pubitemid 46523335)
14. Iron chelators: development of novel compounds with high and selective anti-tumour activity. Kovacevic Z, Kalinowski DS, Lovejoy DB, Quach P, Wong J, Richardson DR, Curr Drug Deliv 2010 PMID:20507267
15. Iron chelators in cancer chemotherapy. Buss JL, Greene BT, Turner J, Torti FM, Torti SV, Curr Top Med Chem 2004 4 1623 1635 10.2174/1568026043387269 15579100 (Pubitemid 39654453)
16. A class of iron chelators with a wide spectrum of potent antitumor activity that overcomes resistance to chemotherapeutics. Whitnall M, Howard J, Ponka P, Richardson DR, Proc Natl Acad Sci U S A 2006 103 14901 14906 10.1073/pnas.0604979103 17003122 (Pubitemid 44527826)
17. Inhibition of malignant cell growth by 311, a novel iron chelator of the pyridoxal isonicotinoyl hydrazone class: effect on the R2 subunit of ribonucleotide reductase. Green DA, Antholine WE, Wong SJ, Richardson DR, Chitambar CR, Clin Cancer Res 2001 7 3574 3579 11705879 (Pubitemid 33069997)
18. A novel mammalian iron-regulated protein involved in intracellular iron metabolism. Abboud S, Haile DJ, J Biol Chem 2000 275 19906 19912 10.1074/jbc.M000713200 10747949 (Pubitemid 30441595)
19. A novel duodenal iron-regulated transporter, IREG1, implicated in the basolateral transfer of iron to the circulation. McKie AT, Marciani P, Rolfs A, Brennan K, Wehr K, Barrow D, Miret S, Bomford A, Peters TJ, Farzaneh F, Hediger MA, Hentze MW, Simpson RJ, Mol Cell 2000 5 299 309 10.1016/S1097-2765(00)80425-6 10882071 (Pubitemid 30628088)
20. Positional cloning of zebrafish ferroportin1 identifies a conserved vertebrate iron exporter. Donovan A, Brownlie A, Zhou Y, Shepard J, Pratt SJ, Moynihan J, Paw BH, Drejer A, Barut B, Zapata A, Law TC, Brugnara C, Lux SE, Pinkus GS, Pinkus JL, Kingsley PD, Palis J, Fleming MD, Andrews NC, Zon LI, Nature 2000 403 776 781 10.1038/35001596 10693807 (Pubitemid 30111839)
21. Comparative studies of duodenal and macrophage ferroportin proteins. Canonne-Hergaux F, Donovan A, Delaby C, Wang HJ, Gros P, Am J Physiol Gastrointest Liver Physiol 2006 290 156 G163 16081760
22. Essential but toxic: controlling the flux of iron in the body. Anderson GJ, Wang F, Clin Exp Pharmacol Physiol 2012 39 719 724 10.1111/j.1440-1681.2011. 05661.x 22211782
23. A ferroportin transcript that lacks an iron-responsive element enables duodenal and erythroid precursor cells to evade translational repression. Zhang DL, Hughes RM, Ollivierre-Wilson H, Ghosh MC, Rouault TA, Cell Metab 2009 9 461 473 10.1016/j.cmet.2009.03.006 19416716
24. The role of the iron responsive element in the control of ferroportin1/IREG1/MTP1 gene expression. Lymboussaki A, Pignatti E, Montosi G, Garuti C, Haile DJ, Pietrangelo A, J Hepatol 2003 39 710 715 10.1016/S0168-8278(03)00408-2 14568251 (Pubitemid 37372178)
25. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Nemeth E, Tuttle MS, Powelson J, Vaughn MB, Donovan A, Ward DM, Ganz T, Kaplan J, Science 2004 306 2090 2093 10.1126/science.1104742 15514116 (Pubitemid 40007660)
26. Overexpression of cellular iron import proteins is associated with malignant progression of esophageal adenocarcinoma. Boult J, Roberts K, Brookes MJ, Hughes S, Bury JP, Cross SS, Anderson GJ, Spychal R, Iqbal T, Tselepis C, Clin Cancer Res 2008 14 379 387 10.1158/1078-0432.CCR-07-1054 18223212 (Pubitemid 351226104)
27. Expression of iron regulatory genes in a rat model of hepatocellular carcinoma. Holmstrom P, Gafvels M, Eriksson LC, Dzikaite V, Hultcrantz R, Eggertsen G, Stal P, Liver Int 2006 26 976 985 10.1111/j.1478-3231.2006.01316.x 16953838 (Pubitemid 44323416)
28. Ferroportin and iron regulation in breast cancer progression and prognosis. Pinnix ZK, Miller LD, Wang W, D'Agostino R, Kute T, Willingham MC, Hatcher H, Tesfay L, Sui G, Di X, Torti SV, Torti FM, Sci Transl Med 2010 2 43 56
29. Unraveling mechanisms regulating systemic iron homeostasis. Finberg KE, Hematol Am Soc Hematol Educ Program 2011 2011 532 537 10.1182/asheducation-2011. 1.532
30. Ferritin stimulates breast cancer cells through an iron-independent mechanism and is localized within tumor-associated macrophages. Alkhateeb AA, Han B, Connor JR, Breast Cancer Res Treat 2013 137 733 744 10.1007/s10549-012- 2405-x 23306463
31. The transferrin receptor part II: targeted delivery of therapeutic agents into cancer cells. Daniels TR, Delgado T, Helguera G, Penichet ML, Clin Immunol 2006 121 159 176 10.1016/j.clim.2006.06.006 16920030 (Pubitemid 44572972)
32. The transferrin receptor part I: biology and targeting with cytotoxic antibodies for the treatment of cancer. Daniels TR, Delgado T, Rodriguez JA, Helguera G, Penichet ML, Clin Immunol 2006 121 144 158 10.1016/j.clim.2006.06. 010 16904380 (Pubitemid 44592578)
33. Iron regulatory proteins are essential for intestinal function and control key iron absorption molecules in the duodenum. Galy B, Ferring-Appel D, Kaden S, Grone HJ, Hentze MW, Cell Metab 2008 7 79 85 10.1016/j.cmet.2007.10.006 18177727
34. Expression of the iron transporter ferroportin in synaptic vesicles and the blood-brain barrier. Wu LJ, Leenders AG, Cooperman S, Meyron-Holtz E, Smith S, Land W, Tsai RY, Berger UV, Sheng ZH, Rouault TA, Brain Res 2004 1001 108 117 10.1016/j.brainres.2003.10.066 14972659 (Pubitemid 38221533)
35. Investigation of the biophysical and cell biological properties of ferroportin, a multipass integral membrane protein iron exporter. Rice AE, Mendez MJ, Hokanson CA, Rees DC, Bjorkman PJ, J Mol Biol 2009 386 717 732 10.1016/j.jmb.2008.12.063 19150361
36. Autosomal-dominant hemochromatosis is associated with a mutation in the ferroportin (SLC11A3) gene. Montosi G, Donovan A, Totaro A, Garuti C, Pignatti E, Cassanelli S, Trenor CC, Gasparini P, Andrews NC, Pietrangelo A, J Clin Invest 2001 108 619 623 11518736 (Pubitemid 32777742)
37. Ferroportin 1 (SCL40A1) variant associated with iron overload in African-Americans. Beutler E, Barton JC, Felitti VJ, Gelbart T, West C, Lee PL, Waalen J, Vulpe C, Blood Cells Mol Dis 2003 31 305 309 10.1016/S1079-9796(03) 00165-7 14636643 (Pubitemid 37441302)
38. Ferroportin and hepcidin: a new hope in diagnosis, prognosis, and therapy for breast cancer. Pogribny IP, Breast Cancer Res 2010 12 314 10.1186/bcr2641 21062518